Search

Zentalis Pharmaceuticals Inc

Ouvert

2.75 2.61

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.61

Max

2.81

Chiffres clés

By Trading Economics

Revenu

-42M

-78M

BPA

-0.59

Employés

106

EBITDA

-42M

-77M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+200.8% upside

Dividendes

By Acuity

Prochains Résultats

6 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-85M

246M

Ouverture précédente

0.14

Clôture précédente

2.75

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 sept. 2026, 23:56 UTC

BorgWarner Inc. is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

29 sept. 2026, 23:56 UTC

Alexandria Real Estate Equities, Inc. is trading modestly higher in after-market hours following a brief gain after Tuesday's close, despite recent lower closes.

29 sept. 2026, 23:56 UTC

Shift4 Payments, Inc. is trading modestly higher in after-market hours, recovering from an initial dip to settle at 0.59%, below its 20-day moving average.

29 sept. 2026, 23:56 UTC

Correlated Moves

Southern Copper Corp is trading higher in after-market hours, supported by gains in the NYLIM FTSE International Equity Currency Neutral ETF amid fluctuating market conditions.

29 sept. 2026, 23:56 UTC

Correlated Moves

Brixmor Property Group Inc traded higher in after-market hours, reflecting a slight uptick amid a modest recovery in Regency Centers Corp.

29 sept. 2026, 23:56 UTC

Houlihan Lokey Inc is trading higher in after-market hours, despite remaining below its 20-day moving average and near the lower end of its one-month range.

29 sept. 2026, 23:56 UTC

In after-market trading, Donaldson Company Inc is slightly higher since Tuesday's close, with a cumulative return peaking at 0.11%.

29 sept. 2026, 23:56 UTC

IDEX Corp's shares have advanced modestly in after-market trading, supported by strong buying interest and remaining above its 20-day moving average.

29 sept. 2026, 23:56 UTC

Columbia Sportswear Co's shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

29 sept. 2026, 23:56 UTC

Correlated Moves

Columbia Banking System Inc. is moving higher in after-market trading, supported by Verizon Communications' new board member announcement and overall market strength.

29 sept. 2026, 23:56 UTC

The Canadian dollar advanced against the Swiss franc, supported by a decline in U.S. job openings, remaining near the upper end of its one-month trading range.

29 sept. 2026, 23:55 UTC

Trane Technologies PLC declined in after-market trading, dipping shortly after 6:00 PM but remaining above its 20-day moving average.

29 sept. 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

29 sept. 2026, 23:55 UTC

CVR Energy Inc experiences routine after-market trading with a slight increase, remaining near the upper end of its one-month range.

29 sept. 2026, 23:55 UTC

Service Corporation International is trading modestly higher in after-market hours, despite remaining below its 20-day moving average amid recent economic data on job openings.

29 sept. 2026, 23:55 UTC

Dolby Laboratories Inc is higher in after-market trading, having peaked earlier but currently remains below its 20-day moving average and near its one-month range low.

29 sept. 2026, 23:55 UTC

In after-market trading, Ryman Hospitality Properties Inc has remained roughly flat, trading within a narrow range around the middle of its one-month trading range.

29 sept. 2026, 23:55 UTC

Inspire Medical Systems Inc has gained slightly in after-market hours, currently positioned above its 20-day moving average and near the upper end of its one-month range.

29 sept. 2026, 23:55 UTC

Tennant Co. traded roughly flat in after-market hours, experiencing a modest uptick from earlier lows while remaining below its 20-day moving average.

29 sept. 2026, 23:55 UTC

TDS is declining in after-market hours, marking its sixth consecutive session lower and remaining notably below its 20-day moving average.

29 sept. 2026, 23:55 UTC

Coca-Cola Co is experiencing a modest gain in after-market trading, currently positioned below its 20-day moving average near the lower end of its one-month range.

29 sept. 2026, 23:55 UTC

AutoNation Inc finished after-market hours higher, recovering from a prior decline, though it remains significantly below its 20-day moving average.

29 sept. 2026, 23:55 UTC

One Liberty Properties Inc is trading lower in after-market hours, positioned near the lower end of its one-month range and below its 20-day moving average.

29 sept. 2026, 23:55 UTC

EPR Properties saw a modest uptick in after-market trading, remaining roughly flat since Tuesday's close and 1.71% below its 20-day moving average.

29 sept. 2026, 23:55 UTC

Ryder System Inc is trading modestly higher in after-market hours, recovering from four consecutive sessions of declines, though still below its 20-day moving average.

29 sept. 2026, 23:55 UTC

Aon PLC experienced a modest decline during after-market hours, trading flat since Tuesday's close and positioned below its 20-day moving average.

29 sept. 2026, 23:55 UTC

CHF/JPY is declining as JOLTs Job Openings fell to 7.079 million in August, below expectations, reflecting ongoing labor market challenges.

29 sept. 2026, 23:55 UTC

Phillips 66 is trading modestly higher in after-market hours, despite remaining below its 20-day moving average and near the lower end of its one-month range.

29 sept. 2026, 23:51 UTC

AGCO Corp is lower in after-market trading, continuing a trend with three consecutive sessions of declines and remaining significantly below its 20-day moving average.

29 sept. 2026, 23:51 UTC

Correlated Moves

ManpowerGroup Inc is trading lower in after-market hours, reflecting a slight decline since Tuesday's close amid broader market weakness.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

200.8% hausse

Prévisions sur 12 Mois

Moyen 8.167 USD  200.8%

Haut 11 USD

Bas 5 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

5

Achat

2

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.